Treatment of Sarcoidosis with Posterior Uveitis or Panuveitis

Clinical Scenario

This protocol addresses sarcoidosis when it presents with posterior uveitis or panuveitis — ocular involvement affecting the back of the eye or the entire uveal tract. In this setting, systemic therapy is usually required rather than local measures alone.

Treatment Approach

The regimen for this specific scenario involves anti-TNF biologic therapy. Experience with biologic agents in sarcoidosis-related uveitis, including refractory cases, informs the approach taken here.

The full protocol — including the specific agents, sequencing, and dosing — is available via the link below.

Instant Access to Structured Evidence-Based Regimens

References

For posterior uveitis or panuveitis, systemic therapy is usually used.

Recent experience suggests that the biologic agents infliximab or adalimumab, both anti-TNF monoclonal antibodies, are also effective.

In uveitis in general – including uveitis related to sarcoidosis – either infliximab or adalimumab has been useful in refractory cases.

View source ↗